We further analyzed the correlation between tertiary lymphoid structure (TLS) and CYT scores and UBE2I expression and found that UBE2I was significantly correlated with TLS and CYT (Fig. 3H-I).Moreover, given that intracellular pathway modulation has been successfully employed in prostate cancer treatment [27], development of specific UBE2I inhibitors could provide a novel therapeutic approach. This evidence concerns the gene UBE2I and prostate carcinoma.